|
May 11
|
HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Apr 25
|
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
|
|
Apr 24
|
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
|
|
Apr 24
|
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
|
|
Apr 16
|
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 10
|
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
|
|
Mar 24
|
Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook
|
|
Mar 22
|
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 22
|
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Mar 6
|
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
|
|
Feb 2
|
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
|
|
Feb 2
|
Best Momentum Stocks to Buy for February 2nd
|
|
Jan 29
|
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
|
|
Jan 29
|
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
|
|
Jan 16
|
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
|
|
Dec 21
|
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
|
|
Nov 3
|
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
|
|
Nov 2
|
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
|